World Journal of Gastroenterology · 2008 · 20 citations · 24 references
PharmacyBiotechnologyPharmacologyDrug DeliveryGene DeliveryGene ExpressionAngiogenesisProtein DeliveryEnzymatic DigestionGreen Fluorescent Protein ReportersProtein FluorescenceTransfection EfficiencyVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsViral Vector Delivery
AIM: To investigate the killing efficiency of a recombinant plasmid containing a thymidine kinase (TK) domain insert driven by the vascular endothelial growth factor receptor 2 (VEGFR2) promoter (KDR) on vascular endothelial cells. METHODS: The KDR-TK fragment was extracted from pBluescript II KDR-TK plasmid by enzymatic digestion with XhoI and SalI. The enhanced green fluorescence protein (EGFP) carrier was extracted from pEGFP by the same procedure. The KDR-TK was inserted into the pEGFP carrier to construct pEGFP-KDR-TK. Using ultrasound irradiation and microbubble, pEGFP-KDR-TK was transferred into human umbilical vein endothelial cells (HUVECs). The transient infection rate was estimated by green fluorescent protein (GFP) expression. Transfected HUVECs, non-transfected HUVECs, and HepG2 cells were cultured in the presence of different concentrations of ganciclovir (GCV), and the killing efficacy of HSV-TK/GCV was analyzed by 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) assay. RESULTS: The recombinant pEGFP-KDR-TK was successfully constructed by inserting the KDR-TK fragment into the pEGFP carrier. Transfected HUVECs showed cytoplasmic green fluorescence, and the transient transfection rate was about 20.3%. Pools of G418-resistant cells exhibited a higher sensitivity to the prodrug/GCV compared to non-transfected HUVECs or non-transfected HepG2 cells, respectively. CONCLUSION: KDR promoter and the suicide gene/prodrug system mediated by diagnostic ultrasound combined with microbubble can significantly kill HUVECs. Such therapy may present a novel and attractive approach to target gene therapy on tumor vessels.
24
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Thomas Boehm, Judah Folkman, Timothy Browder et al. · Nature · 1997 · 1.7K citations
Medicine, Oncology, Pharmacology +16
Gene Therapy Death Prompts Review of Adenovirus Vector
Eliot Marshall · Science · 1999 · 918 citations
Judah Folkman · Scientific American · 1976 · 323 citations
Medicine, Cancer Biology, Oncology +10